Vivo Capital related stories
All articles and analysis
Serán Bioscience snags investment from Bain Capital Life SciencesSerán's existing investor Vivo Capital remains a key shareholder in the company.
Biotech company enGene to go public in Forbion-sponsored SPAC mergerUpon closing of the deal, the combined company will be named enGene Holdings, whose common shares are expected to be listed on the Nasdaq.
Vivo Capital taps Massad as business development mnaging directorMassad is a former global head of business development and investor relations at Highbridge Capital Management.
Fubon Life approves $129m in commitmentsThe Taiwan-based insurance company has backed two private equity funds.
Avistone Pharmaceuticals procures over $200mAvistone Pharmaceuticals, a clinical-stage biotechnology company focused on precision oncology therapeutics, has raised over $200 million in funding.
- VC-backed Ventyx Biosciences goes public
Encinitas, California-based Ventyx Biosciences, a developer of treatments for people with inflammatory diseases and autoimmune disorders, has raised $151.5 million for its IPO after pricing its over 9.4 million shares at $16 per share.
- Neurogastrx rakes in $60m Series B
Neurogastrx, a developer of treatments for gastrointestinal disorders, has secured $60 million in Series B funding.
Impel NeuroPharma goes publicImpel NeuroPharma, a Seattle-based pharmaceutical company, has raised $80 million after pricing its IPO of over 5.3 million shares at $15 per share.
- Immune-Onc scores $73m
Palo Alto, California-based Immune-Onc, a cancer immunotherapy company, has secured $73 million in Series B1 and B2 financing.
- Fortis Therapeutics gathers $40m Series A
Fortis Therapeutics, Inc., an immuno-oncology biotech company, has raised $40 million in Series A financing.